{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:53:01Z","timestamp":1701478381635},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Friedreich ataxia is the most common inherited ataxia in Europe and is mainly caused by biallelic pathogenic expansions of the GAA trinucleotide repeat in intron 1 of the <jats:italic>FXN<\/jats:italic> gene that lead to a decrease in frataxin protein levels. Rarely, affected individuals carry either a large intragenic deletion or whole-gene deletion of <jats:italic>FXN<\/jats:italic> on one allele and a full-penetrance expanded GAA repeat on the other allele.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report here a patient that presented the typical clinical features of FRDA and genetic analysis of <jats:italic>FXN<\/jats:italic> intron 1 led to the assumption that the patient carried the common biallelic expansion. Subsequently, parental sample testing led to the identification of a novel intragenic deletion involving the 5\u2019UTR upstream region and exons 1 and 2 of the <jats:italic> FXN<\/jats:italic> gene by MLPA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>With this case, we want to raise awareness about the potentially higher prevalence of intragenic deletions and underline the essential role of parental sample testing in providing accurate genetic counselling.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-023-01743-0","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:02:47Z","timestamp":1701435767000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel intragenic deletion within the FXN gene in a patient with typical phenotype of Friedreich ataxia: may be more prevalent than we think?"],"prefix":"10.1186","volume":"16","author":[{"given":"Cinthia","family":"Aguilera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Esteve-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"V\u00e9lez-Santamaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rausell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Gargallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garcia-Planells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Al\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Llecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Padr\u00f3-Miquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"1743_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jval.2021.11.1122","volume":"25","author":"K Buesch","year":"2022","unstructured":"Buesch K, Zhang R. POSB355 Health-Related Quality of Life in Friedreich Ataxia: a systematic literature review. Value Heal. 2022;25:229.","journal-title":"Value Heal"},{"key":"1743_CR2","unstructured":"Bidichandani SI, Delatycki MB, Friedreich Ataxia. GeneReviews\u00ae. 2017. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1281\/. Accessed 16 Oct 2022."},{"key":"1743_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/jnc.12317","volume":"126 Suppl","author":"MH Parkinson","year":"2013","unstructured":"Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich\u2019s ataxia: classical and atypical phenotypes. J Neurochem. 2013;126 Suppl:103\u201317.","journal-title":"J Neurochem"},{"key":"1743_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13023-014-0184-7","volume":"9","author":"LA Corben","year":"2014","unstructured":"Corben LA, Lynch D, Pandolfo M, Schulz JB, Delatycki MB. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis. 2014;9:184.","journal-title":"Orphanet J Rare Dis"},{"key":"1743_CR5","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1111\/bph.12470","volume":"171","author":"A Anzovino","year":"2014","unstructured":"Anzovino A, Lane DJR, Huang ML-H, Richardson DR. Fixing frataxin: ironing out the metabolic defect in Friedreich\u2019s ataxia. Br J Pharmacol. 2014;171:2174\u201390.","journal-title":"Br J Pharmacol"},{"key":"1743_CR6","doi-asserted-by":"publisher","first-page":"NS20180060","DOI":"10.1042\/NS20180060","volume":"2","author":"E Clark","year":"2018","unstructured":"Clark E, Johnson J, Dong YN, Mercado-Ayon E, Warren N, Zhai M, et al. Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial Disease. Neuronal Signal. 2018;2:NS20180060.","journal-title":"Neuronal Signal"},{"key":"1743_CR7","doi-asserted-by":"publisher","first-page":"12239","DOI":"10.1073\/pnas.220403797","volume":"97","author":"M Ristow","year":"2000","unstructured":"Ristow M, Pfister MF, Yee AJ, Schubert M, Michael L, Zhang CY, et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci U S A. 2000;97:12239\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1743_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","volume":"271","author":"V Campuzano","year":"1996","unstructured":"Campuzano V, Montermini L, Molt\u00f2 MD, Pianese L, Coss\u00e9e M, Cavalcanti F, et al. Friedreich\u2019s ataxia: autosomal recessive Disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423\u20137.","journal-title":"Science"},{"key":"1743_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s13353-015-0331-4","volume":"57","author":"D Hoffman-Zacharska","year":"2016","unstructured":"Hoffman-Zacharska D, Mazurczak T, Zajkowski T, Tataj R, G\u00f3rka-Skoczylas P, Po\u0142aty\u0144ska K, et al. Friedreich ataxia is not only a GAA repeats expansion disorder: implications for molecular testing and counselling. J Appl Genet. 2016;57:349\u201355.","journal-title":"J Appl Genet"},{"key":"1743_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ana.24595","volume":"79","author":"CA Galea","year":"2016","unstructured":"Galea CA, Huq A, Lockhart PJ, Tai G, Corben LA, Yiu EM, et al. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia. Ann Neurol. 2016;79:485\u201395.","journal-title":"Ann Neurol"},{"key":"1743_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1525-1578(10)60523-5","volume":"6","author":"P Ciotti","year":"2004","unstructured":"Ciotti P, Di Maria E, Bellone E, Ajmar F, Mandich P. Triplet repeat primed PCR (TP PCR) in molecular diagnostic testing for Friedreich ataxia. J Mol Diagn. 2004;6:285\u20139.","journal-title":"J Mol Diagn"},{"key":"1743_CR12","doi-asserted-by":"publisher","first-page":"11101","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinforma. 2013;43:11101\u201333.","journal-title":"Curr Protoc Bioinforma"},{"key":"1743_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jnc.12215","volume":"126","author":"P Vankan","year":"2013","unstructured":"Vankan P. Prevalence gradients of Friedreich\u2019s ataxia and R1b haplotype in Europe co-localize, suggesting a common palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem. 2013;126:11\u201320.","journal-title":"J Neurochem"},{"key":"1743_CR14","unstructured":"Ryan F. European Molecular Genetics Quality Network EMQN Best Practice Guidelines for Molecular Analysis of Friedreich Ataxia. 2001."},{"key":"1743_CR15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.ejhg.5201257","volume":"12","author":"CH Z\u00fchlke","year":"2004","unstructured":"Z\u00fchlke CH, Dalski A, Habeck M, Straube K, Hedrich K, Hoeltzenbein M, et al. Extension of the mutation spectrum in Friedreich\u2019s ataxia: detection of an exon deletion and novel missense mutations. Eur J Hum Genet. 2004;12:979\u201382.","journal-title":"Eur J Hum Genet"},{"key":"1743_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ymgme.2010.07.001","volume":"101","author":"EC Deutsch","year":"2010","unstructured":"Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF, et al. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab. 2010;101:238\u201345.","journal-title":"Mol Genet Metab"},{"key":"1743_CR17","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/archneurol.2011.834","volume":"69","author":"M Anheim","year":"2012","unstructured":"Anheim M, Mariani L-L, Calvas P, Cheuret E, Zagnoli F, Odent S, et al. Exonic deletions of FXN and early-onset Friedreich ataxia. Arch Neurol. 2012;69:912\u20136.","journal-title":"Arch Neurol"},{"key":"1743_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1089\/gtmb.2012.0012","volume":"16","author":"AMW van den Ouweland","year":"2012","unstructured":"van den Ouweland AMW, van Minkelen R, Bolman GM, Wouters CH, Becht-Noordermeer C, Deelen WH, et al. Complete FXN deletion in a patient with Friedreich\u2019s ataxia. Genet Test Mol Biomarkers. 2012;16:1015\u20138.","journal-title":"Genet Test Mol Biomarkers"},{"key":"1743_CR19","doi-asserted-by":"crossref","unstructured":"Nethisinghe S, Kesavan M, Ging H, Labrum R, Polke JM, Islam S et al. Interruptions of the FXN GAA repeat Tract Delay the Age at Onset of Friedreich\u2019s Ataxia in a location dependent manner. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22147507"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01743-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01743-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01743-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:06:30Z","timestamp":1701435990000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01743-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01743-0","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Ethical Committee of Hospital Universitari de Bellvitge and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from the patient and his family for the genetic analysis performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and his family for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Laura Rausell, Pablo Gargallo and Javier Garcia-Planells are employees of Health in Code S.L. All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"312"}}